SNSE Profile
Sensei Biotherapeutics, Inc. is a pioneering biopharmaceutical company focused on the discovery and development of advanced immunotherapies, primarily targeting cancer. The company employs its proprietary ImmunoPhage platform, which utilizes bacteriophage technology to provoke a highly targeted and coordinated immune response. This innovative approach aims to enhance both innate and adaptive immune functions to effectively combat various types of cancer. Sensei Biotherapeutics is also advancing its Tumor Microenvironment Activated Biologics platform, which is designed to activate T-cells within the tumor microenvironment, thereby harnessing their full anti-tumor potential. This platform includes the development of human monoclonal antibodies that are selectively effective in the tumor microenvironment and aim to target critical immune checkpoints or other essential immune pathways.
Among the company’s leading candidates is SNS-101, a monoclonal antibody developed for treating cancer. This therapeutic is designed to target specific cancer-associated antigens and modulate the immune response to improve treatment efficacy. Additionally, Sensei Biotherapeutics is working on SNS-401-NG, an ImmunoPhage-based vaccine intended to target multiple tumor antigens simultaneously, thereby offering a broad-spectrum approach to cancer immunotherapy.
The company has established a collaboration with The University of Washington to research and develop a vaccine for Merkel cell carcinoma, a rare and aggressive form of skin cancer. This partnership underscores Sensei Biotherapeutics’ commitment to advancing innovative treatments through academic and clinical collaborations, aiming to bring new therapeutic options to market.
Formerly known as Panacea Pharmaceuticals, Inc., Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts. The company’s ongoing research and development efforts reflect its dedication to leveraging cutting-edge technology and novel therapeutic platforms to address unmet needs in cancer treatment and improve patient outcomes.
|
